7Baggers
 FDA Acceptance Boosts Outlook Therapeutics Shares Significantly  timothysykes.com Sun, 16 Nov 2025 16:22:00 GMT
 H.C. Wainwright Sticks to Its Hold Rating for Outlook Therapeutics (OTLK)  The Globe and Mail Sun, 16 Nov 2025 00:00:21 GMT
 FDA Accepts Outlook Therapeutics’ BLA Resubmission for ONS-5010  timothysykes.com Sat, 15 Nov 2025 16:24:00 GMT
 Outlook Therapeutics’ FDA Review for ONS-5010 Resubmission  TipRanks Thu, 13 Nov 2025 22:15:31 GMT
 Outlook Therapeutics announces acceptance of BLA for ONS-5010  TipRanks Thu, 13 Nov 2025 17:37:50 GMT
 FDA accepts resubmitted ONS-5010 BLA from Outlook Therapeutics  Ophthalmology Times Thu, 13 Nov 2025 17:13:59 GMT
 Outlook Therapeutics (OTLK) Surges 12% as FDA Accepts ONS-5010 A  GuruFocus Thu, 13 Nov 2025 16:12:36 GMT
 Outlook Therapeutics gets FDA review for wet AMD drug (OTLK)  Seeking Alpha Thu, 13 Nov 2025 15:10:49 GMT
 OTLK Stock Surge: Worth the Investment?  StocksToTrade Thu, 13 Nov 2025 15:05:00 GMT
 Outlook Therapeutics stock soars after FDA accepts BLA resubmission  Investing.com Thu, 13 Nov 2025 14:21:14 GMT
 Outlook Therapeutics Announces Acceptance of Biologics  GlobeNewswire Thu, 13 Nov 2025 13:30:00 GMT
 tc energy extends financial outlook amid strong q3 performance  The Globe and Mail Sat, 08 Nov 2025 11:07:36 GMT
 outlook therapeutics takes another shot at us approval for ophthalmic bevacizumab  Citeline News & Insights Fri, 07 Nov 2025 14:10:28 GMT
 outlook therapeutics resubmits wet amd bla for bevacizumab  Eyes On Eyecare Wed, 05 Nov 2025 19:13:15 GMT
 outlook therapeutics resubmits bla for wet amd treatment by investing.com  Investing.com Australia Tue, 04 Nov 2025 13:51:58 GMT
 outlook therapeutics (otlk) re-submits bla for key eye treatment  GuruFocus Mon, 03 Nov 2025 14:39:32 GMT
 outlook therapeutics resubmits bla for ons-5010  TipRanks Mon, 03 Nov 2025 13:56:16 GMT
 dyne therapeutics to present at upcoming investor conferences  The Manila Times Mon, 03 Nov 2025 12:36:46 GMT
 Outlook Therapeutics resubmits BLA for wet AMD treatment  Investing.com Mon, 03 Nov 2025 08:00:00 GMT

Outlook Therapeutics, Inc
(NASDAQ:OTLK) 

OTLK stock logo

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Ph...

Founded: 2009
Full Time Employees: 14
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends